Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Other Gross PP&E Adjustments (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Other Gross PP&E Adjustments for 15 consecutive years, with $114.5 million as the latest value for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments rose 13.85% to $114.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $114.5 million through Dec 2025, up 13.85% year-over-year, with the annual reading at $114.5 million for FY2025, 13.85% up from the prior year.
  • Other Gross PP&E Adjustments hit $114.5 million in Q4 2025 for Ani Pharmaceuticals, up from -$20.3 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $114.5 million in Q4 2025 to a low of -$60.3 million in Q1 2025.
  • Historically, Other Gross PP&E Adjustments has averaged $25.1 million across 5 years, with a median of $36.2 million in 2021.
  • Biggest five-year swings in Other Gross PP&E Adjustments: surged 34.39% in 2022 and later crashed 217.99% in 2024.
  • Year by year, Other Gross PP&E Adjustments stood at $75.6 million in 2021, then grew by 0.44% to $76.0 million in 2022, then grew by 2.07% to $77.5 million in 2023, then grew by 29.74% to $100.6 million in 2024, then rose by 13.85% to $114.5 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for ANIP at $114.5 million in Q4 2025, -$20.3 million in Q3 2025, and -$40.7 million in Q2 2025.